Amsterdam UMC spin-off PacingCure is the winner of the Venture Challenge at the online edition of the Dutch Life Science Conference on the 26th of November. PacingCure develops precision gene therapies for common cardiac arrhythmias and cardiomyopathies, aiming to restore the natural pacing of the heart. The company is founded on combined research from the departments of Cardiology and Medical Biology of the AMC.
The PacingCure team, consisting of Geert Boink, Hanno Tan and Osne Kirzner, participated in the summer edition of the Venture Challenge. In this 10-week bootcamp program, life science start-ups work to sharpen and validate their business idea. During the program, the participating start-ups produce a venture plan and pitch their business in front of an expert jury. This year, the jury consisting of Carine van den Brink, Eline Vrijland, Andre van de Sande, Kim Lucassen and Geert-Jan Mulder, agreed that “PacingCure is addressing a high unmet medical need that they can target with their gene-therapy. They have identified a clear first orphan indication to prove their technique. Moreover, they are a very experienced team of clinicians.”
PacingCure is awarded €25.000,- in price money that they will invest in the further growth of their company. The vision of the company is to become a world leader in cardiac gene therapy.
PacingCure is developing therapies that offer superior treatment over established implantable and medicinal therapies to patients suffering from severe morbidity and mortality, and a cure for patients who are currently untreatable. Their in-vivo validated gene therapies are injected directly into a small region of the heart using a simple, minimal-invasive procedure.
In the Life Sciences & Health round, 14 researchers have been selected for the Faculty of Impact programme for two years of intensive and personal guidance in entrepreneurship, intellectual property and investment. Four Amsterdam based researchers have been selected as well: Anouk Post (VU), Olivier Lugier (UvA), Felix Paulußen (VU) and Ewelina Weglarz-Tomczak (UvA). A […]
NewsRapid Photonics receives funding from Innovatiefonds Noord-Holland for the development of an innovative production process of photonic chips with lithium niobate. Rapid Photonics B.V. is a spin-off of the Vrije Universiteit Amsterdam. Through the new convertible loan of €300,000, the company will be getting their technology market-ready to produce integrated photonic chips with lithium niobate, […]
NewsThe grant amounts available to both AMC and VUmc will of course be combined again, creating a budget of approximately € 4 million that will be divided over the best PPP-research proposals that we will receive from all of you. Deadline for the pre-application is May 24.
News